ATE210455T1 - Vwf propeptide enthaltendes pharmazeutisches präparat - Google Patents

Vwf propeptide enthaltendes pharmazeutisches präparat

Info

Publication number
ATE210455T1
ATE210455T1 AT98929378T AT98929378T ATE210455T1 AT E210455 T1 ATE210455 T1 AT E210455T1 AT 98929378 T AT98929378 T AT 98929378T AT 98929378 T AT98929378 T AT 98929378T AT E210455 T1 ATE210455 T1 AT E210455T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
preparation containing
vwf propeptide
containing vwf
propeptide
Prior art date
Application number
AT98929378T
Other languages
English (en)
Inventor
Hans-Peter Schwarz
Katalin Varadi
Peter Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of ATE210455T1 publication Critical patent/ATE210455T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98929378T 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat ATE210455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE

Publications (1)

Publication Number Publication Date
ATE210455T1 true ATE210455T1 (de) 2001-12-15

Family

ID=3502803

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation

Country Status (10)

Country Link
US (2) US7005502B1 (de)
EP (1) EP0977584B1 (de)
JP (1) JP4335978B2 (de)
AT (2) AT405485B (de)
AU (1) AU744643B2 (de)
CA (1) CA2288737A1 (de)
DE (1) DE69802918T2 (de)
ES (1) ES2168766T3 (de)
NO (1) NO324064B1 (de)
WO (1) WO1998053848A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033994B2 (en) 1999-12-24 2006-04-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2010222A1 (de) 2006-03-31 2009-01-07 Baxter International Inc. Pegylierter faktor viii
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
TW201731488A (zh) 2007-12-28 2017-09-16 巴克斯歐塔公司 重組ｖｗｆ調配物
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
HRP20130414T1 (en) 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
CA2741634A1 (en) * 2008-10-27 2010-06-03 Baxter International Inc. Models of thrombotic thrombocytopenic purpura and methods of use thereof
WO2011022657A1 (en) 2009-08-20 2011-02-24 Baxter International Inc. Purification of vwf for increased removal of non-lipid enveloped viruses
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN108139682B (zh) 2015-10-02 2020-12-25 Asml荷兰有限公司 量测方法和设备、计算机程序及光刻系统
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
EP3648787B1 (de) 2017-07-07 2024-10-30 Takeda Pharmaceutical Company Limited Behandlung von patienten mit schwerer von-willebrand-krankheit, die sich einem chirurgischen eingriff unterziehen durch verabreichung von rekombinantem vwf
BR112020019057A2 (pt) 2018-03-21 2020-12-29 Baxalta Incorporated Método para obter uma composição, e, composição farmacêutica.
JP2022524291A (ja) 2019-02-01 2022-05-02 武田薬品工業株式会社 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法
WO2021050718A1 (en) 2019-09-11 2021-03-18 Baxalta Incorporated Methods of treatment related to complexes of von willebrand factor and complement c1q
AR121268A1 (es) 2020-02-04 2022-05-04 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase

Also Published As

Publication number Publication date
US7005502B1 (en) 2006-02-28
DE69802918T2 (de) 2003-04-10
DE69802918D1 (de) 2002-01-24
WO1998053848A1 (en) 1998-12-03
AU7915698A (en) 1998-12-30
ATA91797A (de) 1999-01-15
JP4335978B2 (ja) 2009-09-30
EP0977584B1 (de) 2001-12-12
US7557188B2 (en) 2009-07-07
NO995843D0 (no) 1999-11-29
US20060003921A1 (en) 2006-01-05
JP2001527579A (ja) 2001-12-25
NO324064B1 (no) 2007-08-06
AT405485B (de) 1999-08-25
ES2168766T3 (es) 2002-06-16
EP0977584A1 (de) 2000-02-09
CA2288737A1 (en) 1998-12-03
AU744643B2 (en) 2002-02-28
NO995843L (no) 2000-01-27

Similar Documents

Publication Publication Date Title
ATE210455T1 (de) Vwf propeptide enthaltendes pharmazeutisches präparat
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
NO179531C (no) Fremgangsmåte for brönnbehandling
DE69616333D1 (de) Thip zur behandlung von schlafstörungen
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
ATE239474T1 (de) Verwendung von levobupivacain
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
EP1274414A4 (de) Nasale verabreichung von mitteln zur behandlung von gastroparese
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
ATE248218T1 (de) Humane hypertrophe chrondrozyten zelllinien
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ES2120573T3 (es) 24-epi-1-alfa-hidroxivitamina d2 para tratar la osteoporosis.
DE68905479D1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification